Topiramate weight loss in migraine patients
Topiramate weight loss in migraine patients
复制标题
DOI：
10.1016/j.jns.2008.11.014
复制
发表时间：
2009-03-15
影响因子：
4.4
通讯作者：
Volta, Giorgio Dalla
中科院分区：
文献类型：
--
作者：
Alberici, Antonella;Borroni, Barbara;Volta, Giorgio Dalla
托吡酯（TPM）是公认的有效和安全的预防偏头痛。接受TPM给药的显著比例的患者可能显示体重减轻。在癫痫受试者中，高体重指数（BMI）被认为是TPM治疗下体重减轻的预测因素。因此，我们的目的是研究是否共同的临床决定因素可能与TPM体重减轻偏头痛患者。在我们的临床系列研究中，没有发现高BMI是TPM治疗下体重减轻的预测因素。未知的遗传和环境因素，可能会决定TPM治疗下的体重减轻的过程仍然没有确定。(c)2008 Elsevier B.V.保留所有权利。
Topiramate (TPM) is generally recognized efficacious and safe in migraine prevention. A significant proportion of patients undergoing TPM administration may show weight loss. In epileptic subjects, high body mass index (BMI) was found to be predictive of weight loss under TPM therapy. We therefore aimed to study whether common clinical determinants may be associated to TPM weigh loss in migraine patients. In our clinical series, high BMI was not found a predictor of weight loss under TPM treatment. Unknown genetic and environmental factors that may determine the courses of weight loss under TPM therapy are still do be identified. (c) 2008 Elsevier B.V. All rights reserved.